Stryker Corp (SYK) · Oct 29, 2026 · Earnings

Stryker earnings miss as 2026 guidance gets cut

Miss — Adjusted EPS $3.52 vs ~$3.55 consensus

Stryker’s Q3 earnings missed consensus, and the medical-device maker cut its 2026 guidance despite solid organic growth and margin expansion.

Stryker is rebuilding momentum across its MedSurg, Neurotechnology and Orthopaedics franchises after the 2026 cyber incident and while absorbing portfolio changes and acquisition-related complexity. The quarter showed healthy underlying demand, but not enough to meet the market’s already-reduced bar.

The quarter missed consensus on both sales and adjusted earnings. Revenue reached $6.52 billion versus a published consensus of roughly $6.62 billion, while adjusted diluted EPS was $3.52 versus about $3.55. The filing itself says performance “did fall short of our expectations.”

Q3 2026Q3 2025Consensus
Net sales (Consolidated Statements of Earnings)$6.52B (+7.7%)$6.06B$6.62B
Organic sales growth (Sales Growth Analysis)7.7%—9.2% implied
Adjusted diluted EPS (Non-GAAP Reconciliation)$3.52 (+10.3%)$3.19$3.55
Adjusted operating margin (Non-GAAP Reconciliation)26.2%25.6%—

The core franchise is still growing, but the mix is uneven. MedSurg and Neurotechnology grew organic sales 9.1%, while Orthopaedics grew 5.9%; within Orthopaedics, hips declined 1.0% and knees rose only 1.1%, partly offset by 15.8% growth in Ortho Tech. The filing says consolidated organic growth was “primarily driven by increased unit volume.”

Margin execution was better than the headline earnings miss suggests. Adjusted operating margin expanded to 26.2% from 25.6%, and adjusted EPS still grew 10.3%. But that improvement was not enough to overcome sales running below expectations, while reported earnings were hit by $293 million of goodwill impairment and $153 million of structural-optimization charges.

The bigger change is the reset to full-year expectations. Stryker now expects 6.5%–7.0% organic sales growth and $14.80–$14.90 of adjusted EPS, down from the prior 8.3%–9.3% organic-growth target and $14.95–$15.10 EPS outlook. That turns a quarter with decent operational progress into a broader credibility setback for the 2026 plan.

The new $3 billion buyback authorization is supportive but secondary. It adds capital-return capacity after $1 billion of repurchases during the first nine months, but it does not repair the shortfall in operating expectations.

Bottom line: Stryker’s underlying business remains healthy, especially in MedSurg and Neurotechnology, but Q3 missed a lowered bar and the company cut its full-year targets. The filing weakens the near-term growth story more than it strengthens the margin story.

What to watch next

Q3 earnings call, October 29

Original filing on SEC EDGAR

More Stryker Corp news

Stryker earnings miss as 2026 guidance gets cut | SYK Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.